Filing Details
- Accession Number:
- 0001203311-20-000008
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-12 17:38:48
- Reporting Period:
- 2020-02-10
- Accepted Time:
- 2020-02-12 17:38:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1060736 | Seattle Genetics Inc | SGEN | Biological Products, (No Disgnostic Substances) (2836) | 911874389 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1167496 | B Clay Siegall | 21823 30Th Drive Se Bothell WA 98021 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-02-10 | 5,245 | $12.00 | 764,029 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-10 | 5,245 | $116.34 | 758,784 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-02-10 | 5,002 | $12.00 | 763,786 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-10 | 5,002 | $115.38 | 758,784 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-02-10 | 9,939 | $12.00 | 768,723 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-10 | 9,939 | $114.32 | 758,784 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-02-10 | 8,286 | $12.00 | 767,070 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-10 | 8,286 | $113.39 | 758,784 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-02-10 | 5,245 | $0.00 | 5,245 | $12.00 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-02-10 | 5,002 | $0.00 | 5,002 | $12.00 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-02-10 | 9,939 | $0.00 | 9,939 | $12.00 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-02-10 | 8,286 | $0.00 | 8,286 | $12.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 194,062 | 2020-08-27 | No | 4 | M | Direct | |
| 189,060 | 2020-08-27 | No | 4 | M | Direct | |
| 179,121 | 2020-08-27 | No | 4 | M | Direct | |
| 170,835 | 2020-08-27 | No | 4 | M | Direct |
Footnotes
- Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $115.91 to $116.70. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $114.90 to $115.87. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $113.90 to $114.89. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $112.90 to $113.87. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Options vested at a rate of 25% on 8/27/11 and monthly thereafter until all the shares were fully vested on 8/27/14.
Billionaire Hedge Funds
